Literature DB >> 11406188

Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.

P Miu1, K R Jarvie, V Radhakrishnan, M R Gates, A Ogden, P L Ornstein, H Zarrinmayeh, K Ho, D Peters, J Grabell, A Gupta, D M Zimmerman, D Bleakman.   

Abstract

The present study describes the activity of two novel potent and selective AMPA receptor potentiator molecules LY392098 and LY404187. LY392098 and LY404187 enhance glutamate (100 microM) stimulated ion influx through recombinant homomeric human AMPA receptor ion channels, GluR1-4, with estimated EC(50) values of 1.77 microM (GluR1(i)), 0.22 microM (GluR2(i)), 0.56 microM (GluR2(o)), 1.89 microM (GluR3(i)) and 0.20 microM (GluR4(i)) for LY392098 and EC(50) values of 5.65 microM (GluR1(i)), 0.15 microM (GluR2(i)), 1.44 microM (GluR2(o)), 1.66 microM (GluR3(i)) and 0.21 microM (GluR4(i)) for LY404187. Neither compound affected ion influx in untransfected HEK293 cells or GluR transfected cells in the absence of glutamate. Both compounds were selective for activity at AMPA receptors, with no activity at human recombinant kainate receptors. Electrophysiological recordings demonstrated that glutamate (1 mM)-evoked inward currents in human GluR4 transfected HEK293 cells were potentiated by LY392098 and LY404187 at low concentrations (3-10 nM). In addition, both compounds removed glutamate-dependent desensitization of recombinant GluR4 AMPA receptors. These studies demonstrate that LY392098 and LY404187 allosterically potentiate responses mediated by human AMPA receptor ion channels expressed in HEK 293 cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406188     DOI: 10.1016/s0028-3908(01)00027-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 3.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

4.  High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors.

Authors:  John McNeish; Marsha Roach; John Hambor; Robert J Mather; Laura Weibley; John Lazzaro; Justin Gazard; Jacob Schwarz; Robert Volkmann; David Machacek; Steve Stice; Laura Zawadzke; Christopher O'Donnell; Raymond Hurst
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

5.  Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging.

Authors:  Nicholas Jones; Michael J O'Neill; Mark Tricklebank; Vincenzo Libri; Steve C R Williams
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 6.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

Review 7.  Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Authors:  Mark D Black
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

Review 8.  Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Lobna Ibrahim; Ioline D Henter; Carlos A Zarate
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 10.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.